The discovery of dopamine deficiency in the parkinsonian brain

  • O. Hornykiewicz
Part of the Journal of Neural Transmission. Supplementa book series (NEURALTRANS, volume 70)


This article gives a short historical account of the events and circumstances that led to the discovery of the occurrence of dopamine (DA) in the brain and its deficiency in Parkinson’s disease (PD). Some important consequences, for both the basic science and the patient, of the work on DA in the PD brain are also highlighted.


Parkinsonian Brain Basal Ganglion Disorder Catechol Compound Montreal Group Perform Motor Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anden NE, Carlsson A, Dahlström A, Fuxe K, Hillarp NA, Larsson K (1964) Demonstration and mapping out of nigro-striatal dopamine neurons. Life Sci 3: 523–530PubMedCrossRefGoogle Scholar
  2. Barbeau A, Murphy GF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133: 1706–1707PubMedCrossRefGoogle Scholar
  3. Barbeau A, Sourkes TL, Murphy GF (1962) Les catécholamines dans la maladie de Parkinson. In: deAjuriaguerra (ed) Monoamines et système nerveux centrale. Georg, Genève and Masson, Paris, pp 247–262Google Scholar
  4. Bertler Å, Rosengren E (1959a) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15: 10–11PubMedCrossRefGoogle Scholar
  5. Bertler Å, Rosengren E (1959b) On the distribution in brain monoamines and of enzymes responsible for their formation. Experientia 15: 382–383PubMedCrossRefGoogle Scholar
  6. Birkmayer W, Hornykiewicz O (1961) Der L-ioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788PubMedGoogle Scholar
  7. Birkmayer W, Hornykiewicz O (1962) Der L-Dioxyphenylalanin (=DOPA)-Effekt beim Parkinson-Syndrom des Menschen: zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiat Nervenkr 203: 560–574PubMedCrossRefGoogle Scholar
  8. Blaschko H (1957) Metabolismand storage of biogenic amines. Experientia 13: 9–12PubMedCrossRefGoogle Scholar
  9. Carlsson A (1964) Functional significance of druginduced changes in brain monoamine levels. In: Himwich HE, Himwich WA (eds) Biogenic amines. Elsevier, Amsterdam, pp 9–27 (Progr Brain Res 8)Google Scholar
  10. Carlsson A (1965) Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Eichler O, Farah A (eds) 5-Hydroxytryptamine and related indolealkylamines. Springer, Berlin Heidelberg New York, pp 529–592 (Handb Exp Pharmacol vol 19)Google Scholar
  11. Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists. Nature 180: 1200PubMedCrossRefGoogle Scholar
  12. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxy-tyramine in brain. Science 127: 471PubMedCrossRefGoogle Scholar
  13. Cotzias GC, Van Woert MH, Schiffer IM (1967) Aromatic amino acids and modification of Parkinsonism. N Engl J Med 276: 374–379PubMedCrossRefGoogle Scholar
  14. Dahlström A, Fuxe K (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand 62[Suppl 232]Google Scholar
  15. Denny-Brown D (1962) The basal ganglia and their relation to disorders of movement. Oxford University Press, OxfordGoogle Scholar
  16. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236–1239PubMedCrossRefGoogle Scholar
  17. Hardy J, Langston WJ (2004) How many pathways are there to nigral death? Ann Neurol 56: 316–318PubMedCrossRefGoogle Scholar
  18. Hassler R (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 48: 387–476Google Scholar
  19. Hassler R (1967) Private communication to O. Hornykiewicz. Letter dated February 9, 1967Google Scholar
  20. Holtz P, Balzer H, Westermann E, Wezler E (1957) Beeinflussung der Evipannarkose durch Reserpin, Iproniazid und biogene Amine. Arch Exp Path Pharmakol 231: 333–348Google Scholar
  21. Holzer G, Hornykiewicz O (1959) Über den Dopamin-(Hydroxytyramin-) Stoffwechsel im Gehirn der Ratte. Naunyn Schmiedebergs Arch Exp Path Pharmacol 237: 27–33Google Scholar
  22. Hornykiewicz O (1958) The action of dopamine on the arterial pressure of the guinea pig. Br J Pharmacol 13: 91–94Google Scholar
  23. Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in the Substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75: 309–312PubMedGoogle Scholar
  24. Hornykiewicz O (2001a) Brain dopamine: a historical perspective. In: Di Chiara G (ed) Dopamine in the CNS I. Springer, Berlin Heidelberg, pp 1–22 (Handb Exp Pharmacol vol 154/I)Google Scholar
  25. Hornykiewicz O (2001b) How L-DOPA was discovered as a drug for Parkinson’s disease 40 years ago. Wien Klin Wochenschr 113: 855–862PubMedGoogle Scholar
  26. Hornykiewicz O (2002a) Dopamine and Parkinson’s disease. A personal view of the past, the present, and the future. Adv Neurol 86: 1–11Google Scholar
  27. Hornykiewicz O (2002b) Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 17: 501–508PubMedCrossRefGoogle Scholar
  28. Jasper HH (1970) Neurophysiological mechanisms in parkinsonism. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davis, Philadelphia, pp 408–411Google Scholar
  29. Jung R, Hassler R (1960) The extrapyramidal motor systems. In: Field J, Magoun HW, Hall VE (eds) Handbook of Physiology, sect 1. Neurophysiology, vol II. American Physiological Society, Washington DC, pp 863–927Google Scholar
  30. Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature 180: 244–245PubMedCrossRefGoogle Scholar
  31. Poirier LJ, Sourkes TL (1965) Influence of the substantia nigra on the catecholamine content of the striatum. Brain 88: 181–192PubMedGoogle Scholar
  32. Raab W, Gigee W (1951) Concentration and distribution of “encephalin” in the brain of humans and animals. Proc Soc Exp Biol Med 76: 97–100PubMedGoogle Scholar
  33. Sano I (1962) Private communication to O. Hornykiewicz. Letter dated March 20, 1962Google Scholar
  34. Sano I (2000) Biochemistry of the extrapyramidal system. Parkinsonism Relat Disord 6: 3–6CrossRefPubMedGoogle Scholar
  35. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32: 586–587PubMedCrossRefGoogle Scholar
  36. Sourkes TL (2000) How dopamine was recognised as a neurotransmitter: a personal view. Parkinsonism Relat Disord 6: 63–67PubMedCrossRefGoogle Scholar
  37. Vogt M (1952) Die Verteilung pharmakologisch aktiver Substanzen im Zentralnervensystem. Klin Wochenschr 30: 907–908CrossRefGoogle Scholar
  38. Vogt M (1954) The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol 123: 451–481PubMedGoogle Scholar
  39. Vogt M (1973) Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull 29: 168–172PubMedGoogle Scholar
  40. Ward AA (1970) Physiological implications in the dyskinesias. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davis, Philadelphia, pp 151–159Google Scholar
  41. Weber G (1952) Zum Cholinesterasegehalt des Gehirns bei Hirntumoren und bei Parkinsonismus. Bull Schweiz Akad Med Wiss 8: 263–268PubMedGoogle Scholar
  42. Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature 180: 1050–1051PubMedCrossRefGoogle Scholar
  43. Weil-Malherbe H, Bone AD (1958) Effect of reserpine on the intracellular distribution of catecholamines in the brain stem of the rabbit. Nature 181: 1474–1475PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • O. Hornykiewicz
    • 1
  1. 1.Center for Brain ResearchMedical University of ViennaViennaAustria

Personalised recommendations